Evinacumab in children with HoFH: What’s the evidence?
Dr Eliot Brinton, Utah Lipid Center, Salt Lake City, USA discusses the evidence of using Evinacumab in children with Homozygous familial hypercholesterolaemia.
The SHASTA-2 trial: What the results mean for clinicians
Professor Daniel Gaudet, University of Montreal, Canada discusses what the results from the SHASTA-2 trial mean for clinicians
Triglyceride-rich lipoproteins and their remnants: Commentary on the 2021 EAS Consensus Statement
Professor Gary Lewis, Director of the Banting and Best Diabetes Centre at the University of Toronto, Canada, and co-author of the report discusses the evidence presented in this important publication and its implications for clinicians and patients.
ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
Dr Michael Miller, Professor of Cardiovascular Medicine at the University of Maryland, Baltimore, USA, explains that the ACC’s expert consensus decision pathway stratifies patients with atherosclerotic cardiovascular disease (ASCVD) and persistent hypertriglyceridaemia according to their residual LDL-cholesterol (LDL-C) level.
